Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Betamethasone | 5 | 2001 | 24 | 0.930 |
Why?
|
| Glucocorticoids | 5 | 2001 | 222 | 0.810 |
Why?
|
| Obstetric Labor, Premature | 5 | 2005 | 76 | 0.780 |
Why?
|
| Indomethacin | 4 | 2005 | 107 | 0.610 |
Why?
|
| Fetal Membranes, Premature Rupture | 4 | 2004 | 45 | 0.590 |
Why?
|
| Tocolytic Agents | 3 | 2001 | 12 | 0.520 |
Why?
|
| Pregnancy | 21 | 2005 | 2334 | 0.480 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2001 | 91 | 0.390 |
Why?
|
| Prenatal Care | 2 | 2001 | 117 | 0.360 |
Why?
|
| Gestational Age | 6 | 2000 | 389 | 0.300 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 73 | 0.300 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 3 | 2001 | 46 | 0.290 |
Why?
|
| Delivery, Obstetric | 3 | 2001 | 58 | 0.280 |
Why?
|
| Nifedipine | 3 | 1999 | 40 | 0.250 |
Why?
|
| Pre-Eclampsia | 6 | 2004 | 202 | 0.230 |
Why?
|
| Infant, Newborn | 8 | 2004 | 2455 | 0.220 |
Why?
|
| Labetalol | 2 | 1999 | 10 | 0.220 |
Why?
|
| Calcium Channel Blockers | 2 | 1999 | 138 | 0.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2000 | 154 | 0.200 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1999 | 189 | 0.200 |
Why?
|
| Prostaglandin Antagonists | 1 | 2001 | 11 | 0.200 |
Why?
|
| Salvage Therapy | 1 | 2001 | 82 | 0.190 |
Why?
|
| Amniotic Fluid | 1 | 2000 | 30 | 0.180 |
Why?
|
| Fetal Diseases | 1 | 2000 | 64 | 0.180 |
Why?
|
| Cesarean Section | 1 | 2000 | 101 | 0.170 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2000 | 53 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1999 | 34 | 0.170 |
Why?
|
| Papillomavirus Infections | 2 | 2000 | 194 | 0.170 |
Why?
|
| Female | 24 | 2005 | 38074 | 0.170 |
Why?
|
| Uterine Cervical Diseases | 1 | 1999 | 2 | 0.170 |
Why?
|
| Vaginal Diseases | 1 | 1999 | 11 | 0.170 |
Why?
|
| Tumor Virus Infections | 1 | 1999 | 32 | 0.160 |
Why?
|
| Surgical Wound Infection | 1 | 2000 | 168 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 77 | 0.160 |
Why?
|
| Infant, Premature, Diseases | 1 | 1999 | 85 | 0.160 |
Why?
|
| Fluorouracil | 1 | 1999 | 130 | 0.160 |
Why?
|
| Papillomaviridae | 1 | 1999 | 104 | 0.160 |
Why?
|
| Ductus Arteriosus | 1 | 1997 | 13 | 0.150 |
Why?
|
| Vasoconstriction | 1 | 1997 | 81 | 0.150 |
Why?
|
| Sepsis | 1 | 1999 | 233 | 0.140 |
Why?
|
| Hypertension | 3 | 1999 | 1535 | 0.130 |
Why?
|
| Endometritis | 3 | 2000 | 29 | 0.130 |
Why?
|
| Adult | 15 | 2004 | 21403 | 0.130 |
Why?
|
| Humans | 24 | 2005 | 68618 | 0.120 |
Why?
|
| Prospective Studies | 7 | 2004 | 3705 | 0.110 |
Why?
|
| Vagina | 3 | 2004 | 88 | 0.100 |
Why?
|
| Streptococcus agalactiae | 2 | 2001 | 26 | 0.090 |
Why?
|
| Rectum | 2 | 2001 | 62 | 0.090 |
Why?
|
| Chorioamnionitis | 2 | 2000 | 40 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 2 | 2001 | 198 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2001 | 567 | 0.080 |
Why?
|
| Risk Factors | 4 | 2004 | 5731 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 1999 | 1738 | 0.070 |
Why?
|
| Logistic Models | 2 | 2001 | 1420 | 0.070 |
Why?
|
| Fetal Monitoring | 1 | 2005 | 20 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2001 | 2358 | 0.060 |
Why?
|
| Safety | 1 | 2005 | 145 | 0.060 |
Why?
|
| Hyaline Membrane Disease | 1 | 2004 | 10 | 0.060 |
Why?
|
| Emergencies | 3 | 1999 | 107 | 0.060 |
Why?
|
| Body Fluids | 1 | 2004 | 41 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2001 | 92 | 0.060 |
Why?
|
| Time Factors | 2 | 2001 | 4655 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 2001 | 20 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2001 | 46 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 73 | 0.050 |
Why?
|
| Blood Pressure | 4 | 2000 | 1451 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 70 | 0.050 |
Why?
|
| Administration, Oral | 2 | 1999 | 411 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 160 | 0.050 |
Why?
|
| Penicillin G Benzathine | 1 | 2000 | 3 | 0.050 |
Why?
|
| Retreatment | 1 | 2000 | 59 | 0.050 |
Why?
|
| Platelet Activating Factor | 1 | 2000 | 34 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2000 | 133 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2000 | 36 | 0.050 |
Why?
|
| Penicillins | 1 | 2000 | 32 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2001 | 157 | 0.040 |
Why?
|
| Vaginitis | 1 | 2000 | 21 | 0.040 |
Why?
|
| Uterine Cervicitis | 1 | 2000 | 18 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2000 | 53 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2001 | 308 | 0.040 |
Why?
|
| Abdomen | 1 | 2000 | 80 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2000 | 42 | 0.040 |
Why?
|
| Parity | 1 | 1999 | 71 | 0.040 |
Why?
|
| Adolescent | 4 | 2000 | 8912 | 0.040 |
Why?
|
| Incidence | 2 | 2004 | 1603 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2000 | 123 | 0.040 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 1999 | 4 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 1999 | 11 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 334 | 0.040 |
Why?
|
| Birth Weight | 1 | 1999 | 186 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 1998 | 64 | 0.040 |
Why?
|
| Echocardiography | 2 | 2000 | 515 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 659 | 0.040 |
Why?
|
| Actinomycosis | 1 | 1998 | 6 | 0.040 |
Why?
|
| Triplets | 1 | 1997 | 9 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2000 | 264 | 0.040 |
Why?
|
| Twins | 1 | 1997 | 42 | 0.040 |
Why?
|
| Infant, Premature | 1 | 1999 | 284 | 0.040 |
Why?
|
| Hemodynamics | 2 | 1999 | 705 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2001 | 617 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2001 | 39 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1553 | 0.030 |
Why?
|
| South Carolina | 1 | 2001 | 2752 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2004 | 7277 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 498 | 0.030 |
Why?
|
| Electric Impedance | 2 | 2000 | 131 | 0.020 |
Why?
|
| Vascular Resistance | 2 | 1999 | 179 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 1999 | 7029 | 0.020 |
Why?
|
| Middle Aged | 3 | 2000 | 21147 | 0.020 |
Why?
|
| Fetal Organ Maturity | 1 | 2004 | 3 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2004 | 10 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2004 | 64 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 880 | 0.010 |
Why?
|
| Male | 2 | 2000 | 37321 | 0.010 |
Why?
|
| Thorax | 1 | 2000 | 49 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2000 | 134 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2001 | 226 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2000 | 77 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1753 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2000 | 249 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 579 | 0.010 |
Why?
|
| Intrauterine Devices | 1 | 1998 | 15 | 0.010 |
Why?
|
| Heart Rate | 1 | 1999 | 568 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 2279 | 0.010 |
Why?
|